 Treatment with EXG-34217 increased the telomere length of CD34 cells by 1.24-fold ex vivo Telomere flow-FISH study suggests the potential emergence of a cell population with longer telomeres in vivo No acute or long-term adverse effects were observed for 9 months BALTIMORE, Dec. 12, 2022 GLOBE NEWSWIRE Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company ... The post Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in... 